Every compound in this market is sold with an implied history. Sermorelin actually has one, and it is documented at FDA rather than on a vendor page — which makes it the rare case where the record can be checked instead of inferred.
This is research journalism. It reports what the sources state, including the amounts used in trials and on labels where those are on the record, each figure carrying its source and date — and it never tells anyone what to take.
The shortest piece of the releasing hormone that still works
The body's growth-hormone-releasing hormone is 44 amino acids long. Only the first 29 are needed for full releasing activity, and that fragment — GRF(1–29) — is sermorelin.
The whole releasing-factor shelf is a set of answers to one engineering problem: the natural molecule is destroyed in circulation within minutes. Sermorelin does not solve it. Tesamorelin solves it by attaching a hexenoyl group to the full 44-residue sequence. CJC-1295 solves it by substituting amino acids in the 29-residue fragment. The class logic is set out on our secretagogue page.
Two approvals, seven years apart, both now gone
| Application | Brand | Original approval | Status now |
|---|---|---|---|
| NDA 019863 | Geref | 28 December 1990 | Discontinued |
| NDA 020443 | Geref | 26 September 1997 | Discontinued |
Both were sponsored by EMD Serono. The 1990 application covered a small single-ampoule strength; the 1997 application covered larger vial strengths — a split that tracks the compound's two lives, as an agent for provoking a measurable pituitary response and as a treatment.
Attached to every product entry under both applications, FDA's record carries a specific sentence:
"Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons"
That line is the most informative thing on this page. Vendor copy and forum lore routinely explain sermorelin's disappearance as an FDA action against it. The record says the opposite in the regulator's own words: whatever ended Geref, it was not a safety finding and not a failure of effectiveness. FDA maintains that determination because the distinction carries legal weight elsewhere in drug regulation; it does not state the actual reason, and a discontinuation recorded this way is ordinarily commercial.
What its 27 registrations were for
An intervention search of ClinicalTrials.gov returns 27 studies. Reading their titles rather than counting them is where the finding is.
| What the registrations study | Examples |
|---|---|
| Diagnosing growth hormone deficiency — validations of the releasing-hormone-plus-arginine stimulation test | NCT01060488 (phase 3, 69 participants), NCT03018886 (160), NCT00324064 (90) |
| HIV lipodystrophy and abdominal obesity | NCT01263717 (54), NCT00675506 (phase 2, 60) |
| Cognition and ageing | NCT00257712 (phase 2, 151), NCT02553603 (phase 1, 22) |
| Other conditions — acromegaly, heart failure, fatty liver, subfertility | NCT00004332 (148), NCT00791843 (3) |
| Healthy volunteers | NCT00850564 (15 men) |
| Terminated in older adults | NCT01410799 (13), NCT00807365 (5) |
Not one has a muscle, strength or body-composition endpoint in trained adults. The single healthy-volunteer study enrolled 15 men and was a short-term physiological experiment. The two trials that came closest to the ageing-and-body-composition question were both terminated, one with 13 participants and one with 5.
Its 332 PubMed records make it the best-documented injectable secretagogue this site covers — and that literature is endocrinology. A compound that spent three decades as a diagnostic reagent has a large paper trail about pituitary responsiveness and almost nothing about lifters.
What the record supports, and what it does not
Three things can be said with the documents open.
It was a real drug. That is genuinely unusual here, and it means sermorelin has a human safety and pharmacology record built under regulatory supervision rather than assembled from forum reports.
It was not withdrawn for safety or effectiveness. The Federal Register determination settles the most common claim made about it in both directions — it was not banned, and it did not fail.
Nothing in that record is about building muscle. Twenty-seven registrations, thirty-five years, two approvals, and the endpoint is almost always a measured hormone concentration. The compound's documented ability is to make the pituitary release growth hormone, which is the beginning of the question this site asks rather than the answer to it — the distinction between raising a hormone and adding contractile tissue is the one our secretagogue class page exists to draw, and the class-wide ceiling of roughly 1.1 to 1.4 kg of lean mass is set out on the tesamorelin page and the evidence ledger.
For a tested athlete the status is not in doubt: growth hormone, its fragments and its releasing factors are prohibited at all times, and sermorelin is the releasing fragment itself. Drug testing carries the per-compound detail.